Resistance of Cancer Cells to CTL-Mediated Immunotherapy

Name: Resistance of Cancer Cells to CTL-Mediated Immunotherapy
SKU: 23144441
Price: 269.99 AUD
Availability: InStock

Format:

Hardback

Series:

Resistance to Targeted Anti-Cancer Therapeutics

Show Hide Adult Content

$269.99

RRP:: ~~$360.95~~ save $90.96

Available from supplier

Usually ships in 3-4 weeks

0 in Trolley

Price Match

Wrap this item as a gift ($5.90) - add a free gift card on the next page

Buy Now, Pay Later with:

4 payments of $67.50 with Afterpay Learn more

Availability

Delivering to:

Estimated arrival:

Around 9-19 July using International Courier

Description

This comprehensive volume explores the latest research on the mechanisms of resistance in cancer cells to CTL-mediated immunotherapy. Chapter topics discuss cell-mediated immunity as the result of cytotoxic T-lymphocytes (CTL) directed specifically against cancer cells. In addition, the volume reviews how CTL mediate the cytotoxic activity, in large part, by the indication of apoptosis; hence, tumor cells develop anti-apoptotic mechanisms and thereby, resist CTL-induced apoptosis. In order for CTL-mediated antitumor immunotherapy to be effective, it is essential that agents directed against the resistant tumor cells sensitized cancer cells for CTL-mediated apoptosis. Examples of such agents discussed in the volume include are HDAC inhibitors, proteasome inhibitors, Bcl-2 family inhibitors, PARP, antibodies, and more.

Author Biography:

Benjamin Bonavida, Ph.D., is Professor, UCLA David Geffen School of Medicine for the Department of Microbiology, Immunology & Molecular Genetics. He is also Member, Department of Defense Congressionally Directed Medical Research Program, Member, National Cancer Institute SPORE Program, Member, International Scientific Advisory Board of the Israel Cancer Research Foundation, among other accomplishments. He is currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. He has published over 450 papers and reviews, has received more than 7,980 citations, and has edited four Springer volumes. Salem Chouaib, Ph.D., is Head, Cancer Immunology Division at Institut Gustave Roussy. His research focuses on augmenting cytotoxic T cell immunity and studies how tumors evade the immune system. Dr. Chouaib has published more than 239 scientific papers and reviews, and has received more than 5,490 citations.

Release date Australia

June 30th, 2015

Audience

Professional & Vocational

Contributors

Edited by Benjamin Bonavida
Edited by Salem Chouaib

Illustrations

27 Illustrations, color; 11 Illustrations, black and white; XIX, 353 p. 38 illus., 27 illus. in color.

Pages

353

Series

Resistance to Targeted Anti-Cancer Therapeutics

Dimensions

155x235x21

ISBN-13

9783319178066

Product ID

23144441

Customer reviews

Nobody has reviewed this product yet. You could be the first!

Write a Review

Marketplace listings

There are no Marketplace listings available for this product currently.
Already own it? Create a free listing and pay just 9% commission when it sells!

Sell Yours Here

Get free delivery, exclusive deals, and more^*

Non-Fiction Books:

Resistance of Cancer Cells to CTL-Mediated Immunotherapy

Format:

Series:

Buy Now, Pay Later with:

Availability

Description

Author Biography:

Customer reviews

Marketplace listings

Help & options

Filed under...

Get free delivery, exclusive deals, and more*

Buy Now, Pay Later with:

Author Biography:

Get free delivery, exclusive deals, and more^*